Nektar Therapeutics’s Hold Rating Reaffirmed at Jefferies Group (NKTR)
Nektar Therapeutics (NASDAQ:NKTR)‘s stock had its “hold” rating restated by equities researchers at Jefferies Group in a research report issued on Friday, American Banking & Market News reports. They currently have a $11.00 target price on the stock. Jefferies Group’s price objective points to a potential downside of 20.58% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Cowen and Company initiated coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research note to investors on Thursday, September 12th. They set an “outperform” rating and a $17.00 price target on the stock. Analysts at Brean Capital raised their price target on shares of Nektar Therapeutics (NASDAQ:NKTR) from $14.00 to $17.00 in a research note to investors on Thursday, August 15th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Nektar Therapeutics has an average rating of “Buy” and an average price target of $14.33.
Nektar Therapeutics (NASDAQ:NKTR) opened at 11.00 on Friday. Nektar Therapeutics has a 52-week low of $5.65 and a 52-week high of $14.47. The stock’s 50-day moving average is $12.54 and its 200-day moving average is $11.21. The company’s market cap is $1.273 billion.
Nektar Therapeutics (NASDAQ:NKTR) last released its earnings data on Thursday, August 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.07. The company had revenue of $33.86 million for the quarter, compared to the consensus estimate of $26.22 million. The company’s revenue for the quarter was up 43.0% on a year-over-year basis.
Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.